Renaissance of cancer therapeutic antibodies
Renaissance of cancer therapeutic antibodies
In the past five years therapeutic monoclonal antibodies have established themselves as perhaps the most important and rapidly expanding class of therapeutic drugs. More than 25% of pharmacological agents that are currently under development are based on antibodies and the total income generated from them in 2002 exceeded $3 billion, and is predicted to rise to $10–20 billion by 2010. Many experts feel that antibodies directed at cancer targets are likely to dominate the market for the foreseeable future. In this review, we will discuss some of the factors that, after more than 25 years of development, have led to this transformation in the antibody field.
Current technology makes the generation of fully-human antibodies a routine procedure. However, selection of appropriate disease targets still represents a challenge. Here we discuss factors that make an effective antibody target and provide an overview of the major issues that are likely to shape this exciting field over the next decade.
antibodies, cancer therapy, apoptosis, specificity
503-510
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
van de Winkel, Jan G.J.
003d19da-52d5-4e0b-84ef-7a1b42b7ae6d
2003
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
van de Winkel, Jan G.J.
003d19da-52d5-4e0b-84ef-7a1b42b7ae6d
Glennie, Martin J. and van de Winkel, Jan G.J.
(2003)
Renaissance of cancer therapeutic antibodies.
Drug Discovery Today, 8 (11), .
(doi:10.1016/S1359-6446(03)02714-4).
Abstract
In the past five years therapeutic monoclonal antibodies have established themselves as perhaps the most important and rapidly expanding class of therapeutic drugs. More than 25% of pharmacological agents that are currently under development are based on antibodies and the total income generated from them in 2002 exceeded $3 billion, and is predicted to rise to $10–20 billion by 2010. Many experts feel that antibodies directed at cancer targets are likely to dominate the market for the foreseeable future. In this review, we will discuss some of the factors that, after more than 25 years of development, have led to this transformation in the antibody field.
Current technology makes the generation of fully-human antibodies a routine procedure. However, selection of appropriate disease targets still represents a challenge. Here we discuss factors that make an effective antibody target and provide an overview of the major issues that are likely to shape this exciting field over the next decade.
This record has no associated files available for download.
More information
Published date: 2003
Keywords:
antibodies, cancer therapy, apoptosis, specificity
Identifiers
Local EPrints ID: 26324
URI: http://eprints.soton.ac.uk/id/eprint/26324
ISSN: 1359-6446
PURE UUID: 7215bc57-3d06-4023-84b3-6fa386500fe9
Catalogue record
Date deposited: 19 Apr 2006
Last modified: 15 Mar 2024 07:09
Export record
Altmetrics
Contributors
Author:
Jan G.J. van de Winkel
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics